The Use of Neuroimaging to Assess Associations Among Diet, Nutrients, Metabolic Syndrome, and Alzheimer's Disease

Journal of Alzheimer's Disease

Volumn 48, Issue 2, 2015, Pages 303-318

  Pistollato, Francesca ^a   Cano, Sandra Sumalla ^a,b,c   Elio, Iñaki ^a,b,c   Vergara, Manuel Masias ^a,d   Giampieri, Francesca ^a,e   Battino, Maurizio ^a,e  

^a Universidad Europea del Atlántico   (Spain)

^b Universidad Internacional Iberoamericana   (Mexico)

^c Unidad de Nutrición   (Spain)

^d Universidad Internacional Iberoamericana (UNINI)   (Puerto Rico)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Alzheimer's disease; brain anatomy; imaging; magnetic resonance imaging; metabolic syndrome; mild cognitive impairment; nutrient supplementations; nutritional patterns; positron emission tomography; type 2 diabetes

Indexed keywords

HOMOCYSTEINE; POLYUNSATURATED FATTY ACID;

ALZHEIMER DISEASE; CALORIC RESTRICTION; DEMENTIA; DIET; DIET SUPPLEMENTATION; FISH; GLUCOSE BLOOD LEVEL; HUMAN; INTERVENTION STUDY; MEDITERRANEAN DIET; METABOLIC SYNDROME X; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRIENT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VITAMIN SUPPLEMENTATION; ANIMAL; COMPLICATION; DIETARY SUPPLEMENT; FOOD; METABOLIC DISEASES; METABOLISM; PATHOLOGY; PROCEDURES;

ALZHEIMER DISEASE; ANIMALS; DIET; DIETARY SUPPLEMENTS; FOOD; HUMANS; METABOLIC DISEASES; NEUROIMAGING;

EID: 84941277248     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150301     Document Type: Review

References (104)

1. World Alzheimer Report 2009 http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf, Accessed 3/25-15.
2. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12, 383-388.
3. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319.
4. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8, 663-672.
5. Chen Z, Zhong C (2013) Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. Prog Neurobiol 108, 21-43.
6. Wenk GL (2003) Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry 64(Suppl 9), 7-10.
7. Duyckaerts C, Potier MC, Delatour B (2008) Alzheimer disease models and human neuropathology: Similarities and differences. Acta Neuropathol 115, 5-38.
8. Braak H, Del Tredici K (2012) Where, when, and in what form does sporadic Alzheimer's disease begin? Curr Opin Neurol 25, 708-714.
9. Desikan RS, Cabral HJ, Hess CP, Dillon WP, Glastonbury CM, Weiner MW, Schmansky NJ, Greve DN, Salat DH, Buckner RL, Fischl B, Alzheimer's Disease Neuroimaging I (2009) Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain 132, 2048-2057.
10. Mathis CA, Mason NS, Lopresti BJ, Klunk WE (2012) Development of positron emission tomography betaamyloid plaque imaging agents. Semin Nucl Med 42, 423-432.
11. Lister-James J, Pontecorvo MJ, Clark C, Joshi AD, Mintun MA, Zhang W, Lim N, Zhuang Z, Golding G, Choi SR, Benedum TE, Kennedy P, Hefti F, Carpenter AP, Kung HF, Skovronsky DM (2011) Florbetapir f-18: A histopathologically validated Beta-amyloid positron emission tomography imaging agent. Semin Nucl Med 41, 300-304.
12. Tanaka N, Fukushi K, Shinotoh H, Nagatsuka S, Namba H, Iyo M, Aotsuka A, Ota T, Tanada S, Irie T (2001) Positron emission tomographic measurement of brain acetylcholinesterase activity using N-[(11)C]methylpiperidin-4-yl acetate without arterial blood sampling: Methodology of shape analysis and its diagnostic power for Alzheimer's disease. J Cereb Blood Flow Metab 21, 295-306.
13. Zhou M, Wang X, Liu Z, Yu L, Hu S, Chen L, Zeng W (2014) Advances of molecular imaging probes for the diagnosis of Alzheimer's disease. Curr Alzheimer Res 11, 221-231.
14. Lerner AJ (2013) Amyloid imaging: The court of public opinion. Neurology 81, 1108-1109.
15. Romano M, Buratti E (2013) Florbetapir F 18 for brain imaging of beta-amyloid plaques. Drugs Today (Barc) 49, 181-193.
16. Zannas AS, Doraiswamy PM, Shpanskaya KS, Murphy KR, Petrella JR, Burke JR, Wong TZ (2014) Impact of (1)(8)Fflorbetapir PET imaging of beta-amyloid neuritic plaque density on clinical decision-making. Neurocase 20, 466-473.
17. Willette AA, Johnson SC, Birdsill AC, Sager MA, Christian B, Baker LD, Craft S, Oh J, Statz E, Hermann BP, Jonaitis EM, Koscik RL, La Rue A, Asthana S, Bendlin BB (2015) Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement 11, 504-510.e1.
18. Kenna H, Hoeft F, Kelley R, Wroolie T, DeMuth B, Reiss A, Rasgon N (2013) Fasting plasma insulin and the default mode network in women at risk for Alzheimer's disease. Neurobiol Aging 34, 641-649.
19. Cherbuin N, Sachdev P, Anstey KJ (2012) Higher normal fasting plasma glucose is associated with hippocampal atrophy: The PATH Study. Neurology 79, 1019-1026.
20. Pistollato F, Battino M (2014) Role of plant-based diets in the prevention and regression of metabolic syndrome and neurodegenerative diseases. Trends Food Sci Technol 40, 62-81.
21. Blom K, Emmelot-Vonk MH, Koek HL (2013) The influence of vascular risk factors on cognitive decline in patients with dementia: A systematic review. Maturitas 76, 113-117.
22. Ferreira ST, Clarke JR, Bomfim TR, De Felice FG (2014) Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimers Dement 10, S76-S83.
23. Morris JK, Vidoni ED, Honea RA, Burns JM, Alzheimer's Disease Neuroimaging I (2014) Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol Aging 35, 585-589.
24. Rosendorff C, Beeri MS, Silverman JM (2007) Cardiovascular risk factors for Alzheimer's disease. Am J Geriatr Cardiol 16, 143-149.
25. Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, Bäckman L, Hänninen T, Jula A, Laatikainen T, Lindström J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M (2015) A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER):Arandomised controlled trial. Lancet 385, 2255-2263.
26. Sezgin Z, Dincer Y (2014) Alzheimer's disease and epigenetic diet. Neurochem Int 78, 105-116.
27. Otaegui-Arrazola A, Amiano P, Elbusto A, Urdaneta E, Martinez-Lage P (2014) Diet, cognition, and Alzheimer's disease: Food for thought. Eur J Nutr 53, 1-23.
28. Farias GA, Guzman-Martinez L, Delgado C, Maccioni RB (2014) Nutraceuticals: A novel concept in prevention and treatment of Alzheimer's disease and related disorders. J Alzheimers Dis 42, 357-367.
29. de Waal H, Stam CJ, Lansbergen MM, Wieggers RL, Kamphuis PJ, Scheltens P, Maestu F, van Straaten EC (2014) The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: A randomised controlled study. PLoS One 9, e86558.
30. Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, Harrison J, Swinkels SH, Stam CJ, de Waal H, Wurtman RJ, Wieggers RL, Vellas B, Kamphuis PJ (2012) Efficacy of Souvenaid in mild Alzheimer's disease: Results from a randomized, controlled trial. J Alzheimers Dis 31, 225-236.
31. Kamphuis PJ, Verhey FR, Olde Rikkert MG, Twisk JW, Swinkels SH, Scheltens P (2011) Efficacy of a medical food on cognition in Alzheimer's disease: Results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging 15, 720-724.
32. de Wilde MC, Kamphuis PJ, Sijben JW, Scheltens P (2011) Utility of imaging for nutritional intervention studies in Alzheimer's disease. Eur J Pharmacol 668(Suppl 1), S59-S69.
33. Carrillo MC, Sanders CA, Katz RG (2009) Maximizing the Alzheimer's Disease Neuroimaging Initiative II. Alzheimers Dement 5, 271-275.
34. Masdeu JC, Kreisl WC, Berman KF (2012) The neurobiology of Alzheimer disease defined by neuroimaging. Curr Opin Neurol 25, 410-420.
35. Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R, Feng J (2014) (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 7, CD010386.
36. Gu Y, Scarmeas N (2013) Diet and neuroimaging markers of cerebrovascular disease. Curr Nutr Rep 2, 81-89.
37. Murray J, Tsui WH, Li Y, McHugh P, Williams S, Cummings M, Pirraglia E, Solnes L, Osorio R, Glodzik L, Vallabhajosula S, Drzezga A, Minoshima S, de Leon MJ, Mosconi L (2014) FDG and amyloid PET in cognitively normal individuals at risk for late-onset Alzheimer's disease. Adv J Mol Imaging 4, 15-26.
38. Rapoport SI (2008) Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease. Prostaglandins Leukot Essent Fatty Acids 79, 153-156.
39. Basselin M, Ramadan E, Rapoport SI (2012) Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans. Brain Res Bull 87, 154-171.
40. Suto T, Meguro K, Nakatsuka M, Kato Y, Tezuka K, Yamaguchi S, Tashiro M (2014) Disorders of "taste cognition" are associated with insular involvement in patients with Alzheimer's disease and vascular dementia: "Memory of food is impaired in dementia and responsible for poor diet". Int Psychogeriatr 26, 1127-1138.
41. Murphy C (2008) The chemical senses and nutrition in older adults. J Nutr Elder 27, 247-265.
42. Aliani M, Udenigwe CC, Girgih AT, Pownall TL, Bugera JL, Eskin MN (2013) Aroma and taste perceptions with Alzheimer disease and stroke. Crit Rev Food Sci Nutr 53, 760-769.
43. Steinbach S, Hundt W, Vaitl A, Heinrich P, Forster S, Burger K, Zahnert T (2010) Taste in mild cognitive impairment and Alzheimer's disease. J Neurol 257, 238-246.
44. Ismail Z, Herrmann N, Rothenburg LS, Cotter A, Leibovitch FS, Rafi-Tari S, Black SE, Lanctot KL (2008) A functional neuroimaging study of appetite loss in Alzheimer's disease. J Neurol Sci 271, 97-103.
45. Dai Y, Kamal MA (2014) Fighting Alzheimer's disease and type 2 diabetes: Pathological links and treatment strategies. CNS Neurol Disord Drug Targets 13, 271-282.
46. Fawver JN, Ghiwot Y, Koola C, Carrera W, Rodriguez-Rivera J, Hernandez C, Dineley KT, Kong Y, Li J, Jhamandas J, Perry G, Murray IV (2014) Islet amyloid polypeptide (IAPP): A second amyloid in Alzheimer's disease. Curr Alzheimer Res 11, 928-940.
47. de la Monte SM, Tong M (2014) Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol 88, 548-559.
48. Chen YC, Jiao Y, Cui Y, Shang SA, Ding J, Feng Y, Song W, Ju SH, Teng GJ (2014) Aberrant brain functional connectivity related to insulin resistance in type 2 diabetes: A resting-state fMRI study. Diabetes Care 37, 1689-1696.
49. Morris JK, Vidoni ED, Perea RD, Rada R, Johnson DK, Lyons K, Pahwa R, Burns JM, Honea RA (2014) Insulin resistance and gray matter volume in neurodegenerative disease. Neuroscience 270, 139-147.
50. Birdsill AC, Carlsson CM, Willette AA, Okonkwo OC, Johnson SC, Xu G, Oh JM, Gallagher CL, Koscik RL, Jonaitis EM, Hermann BP, LaRue A, Rowley HA, Asthana S, Sager MA, Bendlin BB (2013) Low cerebral blood flow is associated with lower memory function in metabolic syndrome. Obesity (Silver Spring) 21, 1313-1320.
51. Shen L, Ji HF (2015) Associations between homocysteine, folic acid, vitamin B12 and Alzheimer's disease: Insights from meta-analyses. J Alzheimers Dis 46, 777-790.
52. Madsen SK, Rajagopalan P, Joshi SH, Toga AW, Thompson PM, Alzheimer's Disease Neuroimaging I (2015) Higher homocysteine associated with thinner cortical gray matter in 803 participants from the Alzheimer's Disease Neuroimaging Initiative. Neurobiol Aging 36(Suppl 1), S203-S210.
53. Malouf R, Grimley Evans J (2008) Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev, CD004514.
54. Lee YM, Ha JK, Park JM, Lee BD, Moon E, Chung YI, Kim JH, Kim HJ, Mun CW, Kim TH, Kim YH (2015) Apolipoprotein E genotype modulates effects of vitamin B and homocysteine on grey matter volume in Alzheimer's disease. Psychogeriatrics. doi: 10.1111/psyg.12109
55. Rajagopalan P, Hua X, Toga AW, Jack CR Jr, Weiner MW, Thompson PM (2011) Homocysteine effects on brain volumes mapped in 732 elderly individuals. Neuroreport 22, 391-395.
56. Huang CW, Chang WN, Lui CC, Chen CF, Lu CH, Wang YL, Chen C, Juang YY, Lin YT, Tu MC, Chang CC (2010) Impacts of hyper-homocysteinemia and white matter hyper-intensity in Alzheimer's disease patients with normal creatinine: An MRI-based study with longitudinal followup. Curr Alzheimer Res 7, 527-533.
57. Bullo M, Lamuela-Raventos R, Salas-Salvado J (2011) Mediterranean diet and oxidation: Nuts and olive oil as important sources of fat and antioxidants. Curr Top Med Chem 11, 1797-1810.
58. Tortosa A, Bes-Rastrollo M, Sanchez-Villegas A, Basterra-Gortari FJ, Nunez-Cordoba JM, Martinez-Gonzalez MA (2007) Mediterranean diet inversely associated with the incidence of metabolic syndrome: The SUN prospective cohort. Diabetes Care 30, 2957-2959.
59. Razquin C, Martinez JA, Martinez-Gonzalez MA, Mitjavila MT, Estruch R, Marti A (2009) A 3 years follow-up of a Mediterranean diet rich in virgin olive oil is associated with high plasma antioxidant capacity and reduced body weight gain. Eur J Clin Nutr 63, 1387-1393.
60. Donini LM, De Felice MR, Cannella C (2007) Nutritional status determinants and cognition in the elderly. Arch Gerontol Geriatr 44(Suppl 1), 143-153.
61. Scarmeas N, Stern Y, Mayeux R, Luchsinger JA (2006) Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol 63, 1709-1717.
62. Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, Stern Y (2009) Physical activity, diet, and risk of Alzheimer disease. JAMA302, 627-637.
63. Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA (2009) Mediterranean diet and mild cognitive impairment. Arch Neurol 66, 216-225.
64. Scarmeas N, Luchsinger JA, Stern Y, Gu Y, He J, DeCarli C, Brown T, Brickman AM (2011) Mediterranean diet and magnetic resonance imaging-assessed cerebrovascular disease. Ann Neurol 69, 257-268.
65. Singh B, Parsaik AK, Mielke MM, Erwin PJ, Knopman DS, Petersen RC, Roberts RO (2014) Association of mediterranean diet with mild cognitive impairment and Alzheimer's disease: A systematic review and metaanalysis. J Alzheimers Dis 39, 271-282.
66. Titova OE, Ax E, Brooks SJ, Sjogren P, Cederholm T, Kilander L, Kullberg J, Larsson EM, Johansson L, Ahlstrom H, Lind L, Schioth HB, Benedict C (2013) Mediterranean diet habits in older individuals: Associations with cognitive functioning and brain volumes. Exp Gerontol 48, 1443-1448.
67. Mosconi L, Murray J, Tsui WH, Li Y, Davies M, Williams S, Pirraglia E, Spector N, Osorio RS, Glodzik L, McHugh P, de Leon MJ (2014) Mediterranean diet and magnetic resonance imaging-assessed brain atrophy in cognitively normal individuals at risk for Alzheimer's disease. J Prev Alzheimers Dis 1, 23-32.
68. Matthews DC, Davies M, Murray J, Williams S, Tsui WH, Li Y, Andrews RD, Lukic A, McHugh P, Vallabhajosula S, de Leon MJ, Mosconi L (2014) Physical activity, Mediterranean diet and biomarkers-assessed risk of Alzheimer's: A multi-modality brain imaging study. Adv J Mol Imaging 4, 43-57.
69. Joseph J, Cole G, Head E, Ingram D (2009) Nutrition, brain aging, and neurodegeneration. J Neurosci 29, 12795-12801.
70. Mosconi L, Murray J, Davies M, Williams S, Pirraglia E, Spector N, Tsui WH, Li Y, Butler T, Osorio RS, Glodzik L, Vallabhajosula S, McHugh P, Marmar CR, de Leon MJ (2014) Nutrient intake and brain biomarkers of Alzheimer's disease in at-risk cognitively normal individuals: A crosssectional neuroimaging pilot study. BMJ Open 4, e004850.
71. Bowman GL, Silbert LC, Howieson D, Dodge HH, Traber MG, Frei B, Kaye JA, Shannon J, Quinn JF (2012) Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. Neurology 78, 241-249.
72. Annweiler C, Montero-Odasso M, Bartha R, Beauchet O (2012) Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. Neurology 78, 1281; author reply 1281-1282.
73. Schilling S, Tzourio C, Dufouil C, Zhu Y, Berr C, Alperovitch A, Crivello F, Mazoyer B, Debette S (2014) Plasma lipids and cerebral small vessel disease. Neurology 83, 1844-1852.
74. Devore EE, Feskens E, Ikram MA, den Heijer T, Vernooij M, van der Lijn F, Hofman A, Niessen WJ, Breteler MM (2013) Total antioxidant capacity of the diet and major neurologic outcomes in older adults. Neurology 80, 904-910.
75. De Felice FG (2013) Alzheimer's disease and insulin resistance: Translating basic science into clinical applications. J Clin Invest 123, 531-539.
76. Rabe K, Lehrke M, Parhofer KG, Broedl UC (2008) Adipokines and insulin resistance. Mol Med 14, 741-751.
77. Amigo I, Kowaltowski AJ (2014) Dietary restriction in cerebral bioenergetics and redox state. Redox Biol 2, 296-304.
78. Willette AA, Bendlin BB, Colman RJ, Kastman EK, Field AS, Alexander AL, Sridharan A, Allison DB, Anderson R, Voytko ML, Kemnitz JW, Weindruch RH, Johnson SC (2012) Calorie restriction reduces the influence of glucoregulatory dysfunction on regional brain volume in aged rhesus monkeys. Diabetes 61, 1036-1042.
79. Willette AA, Coe CL, Colman RJ, Bendlin BB, Kastman EK, Field AS, Alexander AL, Allison DB, Weindruch RH, Johnson SC (2012) Calorie restriction reduces psychological stress reactivity and its association with brain volume and microstructure in aged rhesus monkeys. Psychoneuroendocrinology 37, 903-916.
80. Ma T, Tan MS, Yu JT, Tan L (2014) Resveratrol as a therapeutic agent for Alzheimer's disease. Biomed Res Int 2014, 350516.
81. Anekonda TS (2006) Resveratrol-a boon for treating Alzheimer's disease? Brain Res Rev 52, 316-326.
82. Witte AV, Kerti L, Margulies DS, Floel A (2014) Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci 34, 7862-7870.
83. Raji CA, Erickson KI, Lopez OL, Kuller LH, Gach HM, Thompson PM, Riverol M, Becker JT (2014) Regular fish consumption and age-related brain gray matter loss. Am J Prev Med 47, 444-451.
84. Yurko-Mauro K (2010) Cognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive decline. Curr Alzheimer Res 7, 190-196.
85. Samieri C, Maillard P, Crivello F, Proust-Lima C, Peuchant E, Helmer C, Amieva H, Allard M, Dartigues JF, Cunnane SC, Mazoyer BM, Barberger-Gateau P (2012) Plasma long-chain omega-3 fatty acids and atrophy of the medial temporal lobe. Neurology 79, 642-650.
86. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR, Jr., Weiner M, Shinto L, Aisen PS (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. JAMA304, 1903-1911.
87. Blasko I, Hinterberger M, Kemmler G, Jungwirth S, Krampla W, Leitha T, Heinz Tragl K, Fischer P (2012) Conversion from mild cognitive impairment to dementia: Influence of folic acid and vitamin B12 use in the VITA cohort. J Nutr Health Aging 16, 687-694.
88. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H (2010) Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial. PLoS One 5, e12244.
89. Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, Smith AD (2013) Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A 110, 9523-9528.
90. Arlt S, Muller-Thomsen T, Beisiegel U, Kontush A (2012) Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer's disease. Neurochem Res 37, 2706-2714.
91. Kontush K, Schekatolina S (2004) Vitamin E in neurodegenerative disorders: Alzheimer's disease. Ann N Y Acad Sci 1031, 249-262.
92. Whalley LJ, Staff RT, Murray AD, Duthie SJ, Collins AR, Lemmon HA, Starr JM, Deary IJ (2003) Plasma vitamin C, cholesterol and homocysteine are associated with grey matter volume determined by MRI in non-demented old people. Neurosci Lett 341, 173-176.
93. Hooshmand B, Lokk J, Solomon A, Mangialasche F, Miralbell J, Spulber G, Annerbo S, Andreasen N, Winblad B, Cedazo-Minguez A, Wahlund LO, Kivipelto M (2014) Vitamin Din relation to cognitive impairment, cerebrospinal fluid biomarkers, and brain volumes. J Gerontol A Biol Sci Med Sci 69, 1132-1138.
94. Soni M, Kos K, Lang IA, Jones K, Melzer D, Llewellyn DJ (2012) Vitamin D and cognitive function. Scand J Clin Lab Invest Suppl 243, 79-82.
95. Scholey A, Bauer I, Neale C, Savage K, Camfield D, White D, Maggini S, Pipingas A, Stough C, Hughes M (2013) Acute effects of different multivitamin mineral preparations with and without Guarana on mood, cognitive performance and functional brain activation. Nutrients 5, 3589-3604.
96. Kennedy DO, Haskell CF, Robertson B, Reay J, Brewster-Maund C, Luedemann J, Maggini S, Ruf M, Zangara A, Scholey AB (2008) Improved cognitive performance and mental fatigue following a multi-vitamin and mineral supplement with added guarana (Paullinia cupana). Appetite 50, 506-513.
97. Hord NG, Tang Y, Bryan NS (2009) Food sources of nitrates and nitrites: The physiologic context for potential health benefits. Am J Clin Nutr 90, 1-10.
98. Presley TD, Morgan AR, Bechtold E, Clodfelter W, Dove RW, Jennings JM, Kraft RA, King SB, Laurienti PJ, Rejeski WJ, Burdette JH, Kim-Shapiro DB, Miller GD (2011) Acute effect of a high nitrate diet on brain perfusion in older adults. Nitric Oxide 24, 34-42.
99. Poly C, Massaro JM, Seshadri S, Wolf PA, Cho E, Krall E, Jacques PF, Au R (2011) The relation of dietary choline to cognitive performance and white-matter hyperintensity in the Framingham Offspring Cohort. Am J Clin Nutr 94, 1584-1591.
100. Bigford GE, Del Rossi G (2014) Supplemental substances derived from foods as adjunctive therapeutic agents for treatment of neurodegenerative diseases and disorders. Adv Nutr 5, 394-403.
101. van Wijk N, Broersen LM, de Wilde MC, Hageman RJ, Groenendijk M, Sijben JW, Kamphuis PJ (2014) Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination. J Alzheimers Dis 38, 459-479.
102. Shah RC, Kamphuis PJ, Leurgans S, Swinkels SH, Sadowsky CH, Bongers A, Rappaport SA, Quinn JF, Wieggers RL, Scheltens P, Bennett DA (2013) The S-Connect study: Results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. Alzheimers Res Ther 5, 59.
103. Ellis KA, Rowe CC, Villemagne VL, Martins RN, Masters CL, Salvado O, Szoeke C, Ames D, group Ar (2010) Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement 6, 291-296.
104. Arab L, Sabbagh MN (2010) Are certain lifestyle habits associated with lower Alzheimer's disease risk? J Alzheimers Dis 20, 785-794.